Navigation Links
Coronado Biosciences Closes $25.8M in Series C Financing
Date:7/6/2011

NEW YORK, July 6, 2011 /PRNewswire/ -- Coronado Biosciences, a biopharmaceutical company focused on novel immunotherapy agents for inflammatory diseases and cancer, today announced that it closed a $25.8 million Series C financing led by National Securities Corporation.

Coronado plans to use the proceeds from the financing to advance its pipeline, including funding a Phase II study of the company's lead development candidate, CNDO-201 for the treatment of Crohn's Disease and a Phase I/II study of CNDO-109 for the treatment of relapsed Acute Myeloid Leukemia (AML).  Each of these drugs is a novel therapy that has achieved clinical proof-of-concept in indications with unmet medical needs. CNDO-201 is also in development for other autoimmune diseases, including ulcerative colitis and multiple sclerosis.

CNDO-201 (Trichuris suis ova) is a novel, orally administered, natural immunomodulator that regulates T-Cells and inflammatory cytokines.  The use of porcine whipworm ova represents a novel approach and mechanism of action to treating autoimmune diseases that is based on the "hygiene hypothesis."  CNDO-201 has demonstrated meaningful clinical activity and a good safety profile in a three independent investigator sponsored clinical trials.  A Company sponsored Phase II double-blind, placebo controlled trial of CNDO-201 for the treatment of Crohn's Disease is scheduled for initiation in early 2012.  

CNDO-109 is a novel anti-cancer drug that primes natural killer (NK) cells without the need for cytokine (IL-2) treatment and shows significant potential for the treatment of hematological and solid tumors. CNDO-109 has produced impressive results in a Phase I clinical trial in patients with AML and demonstrated preclinical activity in multiple myeloma, breast cancer, prostate cancer and ovarian cancer.  Coronado plans to initiate a Phase I/II dose escalation and expansion trial in patients with relapsed AML in 2012.  

About Coronado Biosciences

Coronado BioSciences is a biopharmaceutical company focused on novel immunotherapy agents for inflammatory diseases and cancer that target major unmet clinical needs in autoimmune disease and cancer.  Founded in 2006, Coronado is based in New York, NY. For more information, please visit www.coronadobiosciences.com.

Contact Information:
Investor Relations
Marcy Nanus, Vice President
The Trout Group, LLC.
646-378-2927; mnanus@troutgroup.com

Media Relations
Dennis S. Dobson Jr., CEO
Dobson Media Group
203-258-0159


'/>"/>
SOURCE Coronado Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
2. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
3. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
4. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
5. Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
6. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
7. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
8. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
9. Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics®
10. BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow
11. Cell Biosciences Acquires Brightwell Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... their offering. ... The global chromatography market to grow at a ... Market 2016-2020, has been prepared based on an in-depth market analysis with ... growth prospects over the coming years. The report also includes a discussion ...
(Date:12/8/2016)... , December 8, 2016 ... "Sugar-Based Excipients Market by Product (Actual Sugars, Sugar ... (Filler & Diluent, Tonicity Agents), Formulation (Oral, Topical, ... MarketsandMarkets, the market has witnessed healthy growth during ... at a CAGR of 4.3% between 2016 and ...
(Date:12/8/2016)... , Dec. 8, 2016  Agenovir Corporation, a ... novel antiviral therapeutics, today announced that it appointed ... officer and a member of the board of ... executive with a deep background in both founding ... founder of Agenovir, co-president of Chan Zuckerberg  Biohub ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had joined the Pharmaceutical ... a non-profit organization to unite pharmaceutical and healthcare companies that share a vision ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
Breaking Medicine News(10 mins):